Excerpts

Depending on health insurance policies, treatment and follow-up costs may be covered by health insurances, but there may be significant differences between several countries.

Thus, among the 81 patients with breast cancer or gynecological malignancies who underwent molecular profiling (11/81, 13.6%) experienced a highly significant clinical improvement (major clinical benefit) through precision oncology.

Even though in our center alcohol consumption and HCV infection were the leading causes of HCC, we observed, in the four-year period analyzed, a decreasing trend in the relative weight of HCV infection (from 30.9% to 22.5% of cases) (both in treated and active HCV) and, on the other hand, an increase in ALD- and MASLD-related HCC.

There was an increasing trend in the proportion of patients with ALD and MASLD, while a decline in HBV and HCV was observed.

Furthermore, the soluble cytokine receptor IL-6Rα(s-IL-6Rα) and the associated soluble gp130 (s-gp130) showed a trend towards the same prediction.

In our previous study [ 20 ], supportive therapy (antiemetics, erythropoietins, colony-stimulating growth factors, and hypocalcemia medications) accounted for 4.6% of the total pharmaceutical expenditure for the treatment of solid tumors in patients treated in the routine healthcare setting, and although this percentage is low, it showed a decreasing trend along the years, with only 1.4% in 2019.

Hypofractionation poses concerns, particularly with limited information on hypofractionated PMRT amid an increasing trend of breast reconstruction after mastectomy [ 5 , 6 ].

The comparison of the two cohorts at different times and by different teams allowed confirmation of the consistency of the PALCOM model based on: (a) the homogeneity of the socio-demographic and clinical data; (b) the lack of significant differences in the distribution of the frequencies of the levels of complexity; (c) the highly significant differences in the frequencies of the different domains of the scale according to the assigned level; and (d) the highly significant differences in 6-month mortality according to the assigned level. 3.2.

Of the 30 blood tests studied, an increasing trend in eight (27%) was associated with eight cancer types, and a decreasing trend in 17 (57%) with 10 cancer types.

Both bacteria showed a trend towards better PFS and OS in the group with the bacterium, and particularly the group with Bacteroides stercoris showed significantly better PFS than the group without the bacteria.

Observing distinct patterns of intratumor heterogeneity ( Figure 1 ), we further found significant or borderline significant differences between the redox indices of the OAs and RAs of each respective line, except for Fp concentration of the C8161 tumor line ( Table 1 ).

Although the role of neutrophils in CLL has traditionally been underestimated, recent studies have brought attention to a notable trend: CLL patients exhibit a higher inclination for NETs release compared to their healthy counterparts.

A pilot cohort of sera from patients with RMS showed a trend towards higher exosomal miR-1246 levels in serum when compared with a separate control cohort, suggesting its origin from RMS tumors in these patients.

Interestingly, subgroup analysis showed a trend toward better outcomes with paclitaxel plus trastuzumab in patients with longer interval between final dose of trastuzumab and paclitaxel plus trastuzumab.

QLQ-C30 and QLQ-STO22 scores showed a favorable trend in trastuzumab plus chemotherapy compared to chemotherapy alone.

We note that these values are averaged and do not reflect interpatient variations, which may be significant for certain parameter configurations.

AML cases showed a trend of correlation of NCAM1 with fibrosis, but case numbers were too low for statistical analysis. 3.2.

A trend toward significance revealed higher local control (LC) rates in patients with a duration of symptoms lasting less than four months from the onset of the disease to the initial consultation (97.7% vs. 84.3%; p = 0.061).

Interestingly, our group of patients with no re-resection radiotherapy showed a trend towards a higher rate of LR.

The XELOXA trial comparing 5-FU to a combination of CAPOX showed a trend toward benefit from the addition of oxaliplatin in terms of DFS and OS in elderly patients, although this was diminished compared to younger patients and was not statistically significant [ 66 , 67 ].

Sixty-seven percent of cases are now diagnosed incidentally [ 4 ], resulting in a decreasing trend in tumor size and stage [ 5 ].

There was also a clear trend toward less positive findings in papillary and chromophobe RCC cases.

Over the past decade, there has been an increasing trend toward the use of DECT for the evaluation of renal lesions [ 17 , 22 , 23 , 24 ].

There was no significant association between the other exposures related to contraception, parity, menopause, hormone replacement therapy, and fertility with all-cause mortality across the survival time intervals; however, there was a marginally significant association between age at menarche >14 years old and mortality in the intermediate survival interval of 6 to <10 years compared to age at menarche ≤12 years old (HR 1.60; 95% CI 1.01, 2.52; p < 0.05).

A further subpopulation analysis, including 70 patients (85%) without metastases at presentation, revealed that rWIR as a binary variable nearly approached significance, suggesting an association with EFS (HR: 2.3; 95% CI: 1.0–5.2) ( Table 3 ). rWIR as a continuous variable was significantly associated with EFS (HR: 0.7; 95% CI: 0.5–0.9).